News and Announcements
Dimerix Bioscience Receives Human Ethics Committee Approval to Commence Phase II Kidney Disease Trial
- Published September 29, 2014 3:38PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29 September 2014 Melbourne, Australia –Dimerix Bioscience Limited today announced receipt of ethics committee approval under the Clinical Trial Notification scheme of the Australian Therapeutic Goods administration to commence its Phase II clinical trial of DMX200 in patients with Chronic Kidney Disease.
Recruitment of patients at the Austin Hospital is expected to commence shortly. The study will investigate the effect of DMX200 on proteinuria in patients with pre existing chronic kidney disease. The DMX200 treatment involves patients who are currently treated with irbesartan, an angiotensin receptor blocker, also taking propagermanium, an anti-inflammatory molecule which acts through the chemokine 2 receptor. The study will be completed under the supervision of Professor David Power, Director of Nephrology at the Austin Hospital, as Principal Investigator.
The therapeutic rationale for DMX200 was developed from Dimerix’s core patented technology, known as Receptor – Heteromer Identification Technology (Receptor – HIT) which can be used to elucidate receptor (or drug target) interactions. Applying this technology to receptors such as G-protein coupled receptors (GPCR’s), Dimerix is able to identify differences in signalling behaviour when receptors interact as heteromers, as expected in vivo, compared with the traditional analysis of single target receptors in isolation.
Executive Chairman, Dr James Williams said “This is an exciting step for Dimerix as we focus on establishing clinical proof of concept for the DMX200 therapy in an area of unmet clinical need. We look forward to working with Professor Power and his team at the Austin hospital.”
For more information please contact:
Dr James Williams
Executive Chairman, Dimerix Bioscience Limited
Email: [email protected]
About Dimerix:
Dimerix’s lead therapy, known as DMX200, is targeted at treating patients with chronic kidney disease. The initial focus is to provide a treatment for persistent proteinuria (abnormally high levels of protein in the urine) caused by chronic kidney disease. The intention is to target rare forms of kidney disease for which Dimerix believes it may be able to obtain regulatory approval in major jurisdictions for an “orphan drug”. Information on
Dimerix is available at its website www.dimerix.com.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
